Bli medlem
Bli medlem

Du är här


Recipharm AB: Recipharm and Pharmanest form collaboration for commercial manufacture and supply of SHACT

Recipharm Karlskoga AB, specialized in the manufacture of semi-solid
products, and Pharmanest AB, a Stockholm-based pharmaceutical company
specializing in developing products for local pain relief in
obstetrics and gynecology, are pleased to announce the formation of a
new pharmaceutical manufacturing contract for SHACT.

Every year, millions of women around the world experience pain and
discomfort during IUD insertion (intrauterine contraception). There
are few treatment options with proven efficacy and safety available
to these women. SHACT is a product based on an innovative formulation
of lidocaine, a well-known anesthetic, and a proprietary application
device developed to simplify topical application in the cervix and
uterus. SHACT has demonstrated convincing Phase II efficacy data as
local anesthesia in connection with IUD insertion and also recently
reported positive data from a hysteroscopy study.

Recipharm and Pharmanest have reached a milestone in their existing
collaboration and Pharmanest is now preparing its candidate SHACT for
launch. Additionally, the companies have reached a long term
agreement for commercial manufacturing, with the precise product
launch date to be announced later. Jointly, the two companies will
offer commercial supply to any market that Pharmanest determine to
enter for supply and sales of their first pharmaceutical product

Ingela Palmkvist, General Manager at Recipharm in Karlskoga,
commented: "I really look forward to closely following the
introduction of this product to various markets. Indeed, I believe it
will make a highly significant difference to patients."

Gunilla Lundmark, CEO at Pharmanest said: "I am very pleased that
Pharmanest and Recipharm have entered into this new collaboration
following the product development success achieved to date. Given the
strong clinical data we are now rapidly moving toward
commercialization. We look forward to working closely with Recipharm
for the commercial manufacture of the product and, indeed, to pooling
our respective skills and capabilities to supply the pharmaceutical
product to key target markets."

For more information contact:

Ingela Palmkvist, General Manager Recipharm Karlskoga AB
E-mail:, phone: +46 (0)8 602 52 00

Gunilla Lundmark, CEO Pharmanest AB
E-mail:, phone: +46 (0)709 749 057

For media enquiries, please contact Tristan Jervis or Alex Heeley at
De Facto Communications on: or

Phone: +44 (0) 207 861 3019/3043
About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden
employing some 1,500 employees. Recipharm offers manufacturing
services of pharmaceuticals in various dosage forms, production of
clinical trial material and pharmaceutical product development.
Recipharm currently manufactures more than 200 different products to
both Big Pharma and smaller research- and development companies.
Recipharm's turnover is approximately SEK 2.1 billion and the Company
operates development and manufacturing facilities in Sweden, France,
the UK, Germany and Spain and is headquartered in Jordbro, Sweden.
The Recipharm B-share (RECI B) is listed on Nasdaq OMX Stockholm.

For more information on Recipharm and our services, please visit

About Pharmanest AB
Pharmanest is a Stockholm-based pharmaceutical company specializing in
developing products for local anaesthesia in gynecology and
obstetrics. For more information, please visit

SHACT is a proprietary 4 % lidocaine formulation developed by
Pharmanest, and patent applications are pending worldwide. SHACT is
applied topically in the cervix and uterus with a device developed by
Pharmanest. SHACT is thermogelling and becomes a gel at body
temperature, which minimizes the leakage from the site of
application. SHACT has a rapid onset of action and is easy to apply
for healthcare professionals. For more information on Pharmanest and
our services, please visit

Recipharm AB (publ)
Corporate identity number 556498-4825
Address Lagervägen 7, SE-136 50 Jordbro Telephone 46 8 602 52 00
Fax 46 8 81 87 03,


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.